TYROSINE KINASE 2 INHIBITOR
Sotyktu is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis in adults 18 and older who are candidates for phototherapy or systemic therapy. Sotyktu is also known by its drug name, deucravacitinib.
Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor. Sotyktu is believed to work by decreasing the amount of certain molecules that cause inflammation. In people with psoriasis, Sotyktu has been shown to decrease psoriasis severity and skin coverage, and symptoms like pain, burning, skin tightness, itching, and stinging.
How do I take it?
Sotyktu is taken orally as a tablet once a day.
Common side effects of Sotyktu include upper respiratory infections like the common cold, sore throat, and sinus infections; cold sores (herpes simplex); canker sores; inflamed hair pores; and acne.
More serious side effects associated with Sotyktu include serious allergic reactions, infections, cancer, and muscle problems.
For more information, visit:
Sotyktu — Bristol Myers Squibb